| Date | News & Events | Location |
| 12/20/2007 | • Thrombotargets to open new facilities in the Mediterranian Technological Park, Spain, this January. | Durham, NC, US |
| 11/5/2007 | Thrombotargets Corp is Proud to Announce its Second Orphan Drug Designation for TT-103MH for The Treatment Of Bleeding Episodes, now in Von Willebrand Patients. | Durham, NC, US |
| 10/10/2007 | Thrombotargets Corp is proud to announce the incorporation of Maria E. Pizzigatti Correa as a New member of the Scientific Advisory Board of Thrombotargets | Durham, NC, US |
| 7/20/2007 | Thrombotargets Corporation and Dr. Cam Patterson, Director of the Carolina Cardiovascular Biology Center at the University of North Carolina to create a Joint Venture for the exploitation of their technologies. | Durham, NC, USA |
| 7/16/2007 | Thrombotargets Corp announced today that it has submitted its Orphan Drug Application of TT-103MH to the FDA for bleeding treatment in von Willebrand patients | Durham, NC, USA |
| 6/18/2007 | Thrombotargets Europe Receives $1Million Profit Grant for Development of Hemostatic Programs | Barcelona, Spain |
| 6/18/2007 | Thrombotargets Corp. and Magellan Bioscience Group, Inc. to collaborate on identification of novel hits from both marine derivate and natural products. | Durham, North Carolina |
| 6/14/2007 | Steven A. Hite appointed Chief Operating Officer of Thrombotargets Corp. | Durham, NC (USA) |
| 6/1/2007 | Thrombotargets Corp. and Chemotargets to collaborate on identification of novel hits related with cardiovascular diseases | Barcelona, Spain |
| 6/1/2007 | Thrombotargets Corp. Announces the Membership of Its New Scientific Advisory Board | Durham, North Carolina |
| 4/23/2007 | Thrombotargets Corp. and Specs achieve milestone in their Drug Discovery collaboration and announce the beginning of a new Anticoagulant program. | Durham, North Carolina |
| 4/16/2007 | Thrombotargets Corporation and Instituto Biomar to collaborate on identification and optimization of new drug candidates | Durham, North Carolina |
| 2/13/2007 | Thrombotargets Corporation Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Procoagulant Agent, TT-103MH, in the Treatment of Bleeding Episodes in Hemophiliacs | Miami, Florida |
| 2/4/2007 | Thrombotargets Europe S.L. today announces the incorporation of Dr. Juan Ramón Rodriguez as a R&D Director | Madrid, Spain |
| 2/3/2007 | Thrombotargets Europe inagurates new facilities at the National Biotechnology Centre (CNB) in Madrid, Spain | Madrid, Spain |
| 1/17/2007 | Thrombotargets Corporation relocates to Research Triangle Park in North Carolina | Miami; Florida, USA |
| 12/16/2006 | Thrombotargets Corp. and Lippso achieve milestone in their Drug Discovery collaboration and announce the beginning of a new Anticoagulant program. | Miami, Florida, USA |
| 12/16/2006 | Thrombotargets Europe Announces Second Round of Public Funding from ENISA | Madrid, Spain |
| 12/16/2006 | Thombotargets Corp attended the 2006 JAFCO Biotech Conference in Japan last November. | Miami; Florida, USA |
| 12/16/2006 | Thrombotargets Announces a Wide Collaborative Scientific Agreement with Prestigious Spanish and American Research Centers | Barcelona, Spain. |
| 12/11/2006 | Thrombotargets Corp announced today that it has submitted its Orphan Drug Application of TT-103MH to the FDA for bleeding treatment in Haemophilc patients | Miami, Florida, USA |
| 9/21/2006 | Thrombotargets Europe and Haemophilia Unit of Valle Hebron Hospital To Sign a Collaborative Scientific Agreement | Barcelona, Spain |
| 9/20/2006 | Thrombotargets Corp. and Asinex achieve milestone in their Drug Discovery collaboration and announce the beginning of a new Antifibrinolytic program. | Miami, Florida. |
| 6/20/2006 | Thrombotargets Corp participated in BioVenture Forum East 2006 | Jersey City, NJ, |
| 6/7/2006 | Thrombotargets announces US $ 6.5 million private funding from Biotech Angels | Barcelona, Spain. |
| 5/31/2006 | Thrombotargets Europe and IUCT to collaborate on identification and optimization of new drug candidates | Barcelona, Spain. |
| 5/15/2006 | Thrombotargets Corp participated in BioWindhover 2006: “Partnering Conference For Decision Makers” | Washington DC |
| 5/5/2006 | Thrombotargest Corp today announced the initiation of TT-103 Preclinical Phase | Miami, Florida, |
| 5/3/2006 | Thrombotargets Corp. and ASINEX to collaborate on identification and optimization of new drug candidates | Miami, Florida |
| 4/13/2006 | Thrombotargets Corp. and SPECS to collaborate on identification and optimization of new drug candidates | Miami, Florida |
| 2/15/2006 | Thrombotargets Corp. and Lippso to collaborate on identification and optimization of new drug candidates | Miami, Florida |
| 2/1/2006 | Thrombotargets Corp. announces formulation feasibility study of TT-103 with Cirrus Pharmaceuticals, Inc (North Carolina) | Miami, Florida |
| 2/1/2006 | Thrombotargets Corp. and Villapharma Research to collaborate on identification and optimization of new drug candidates | Miami, Florida |
| 12/20/2005 | Thrombotargets Europe Announces Public Funding from ENISA | Madrid, Spain |
| 9/13/2005 | Thrombotargets Europe Announces Public Funding from CDTI | Madrid, Spain |
| 6/22/2005 | Thrombotargets Europe Announces Private Funding from Biotech Angels Investment | Barcelona, Spain |
| 3/1/2005 | Thrombotargets Europe and Cardiovascular Reasearch Center (ICCC, CSIC) To Sign a Collaborative Scientific Agreement | Barcelona, Spain |